VBI Vaccines' Pan-Coronavirus Vaccine Offers Broad Protection Against Variants
VBI Vaccines' pan-coronavirus vaccine candidate, VBI-2901, demonstrated broad and durable protection against variants of concern in a Phase I trial involving 101 adults who had received mRNA COVID vaccines. The vaccine produced high neutralizing responses against multiple COVID-19 variants, including Wuhan, Delta, Beta, and Omicron BA.5, as well as animal coronaviruses. The protective titers remained stable at the six-month interim data point, with no safety concerns. Participants with low baseline neutralization titers showed the greatest vaccine-induced boosting effects. VBI's stock rose over 18% following the positive clinical data.